BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 245.23 Thousand CAD | 23.73% |
| 2023 | 1.18 Million CAD | -14.94% |
| 2022 | 1.39 Million CAD | 179.15% |
| 2021 | 500 Thousand CAD | -89.37% |
| 2020 | 4.7 Million CAD | 34.44% |
| 2019 | 3.49 Million CAD | 1309.23% |
| 2018 | 248.19 Thousand CAD | -31.13% |
| 2017 | 360.38 Thousand CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | -100.0% |
| 2014 | 342.15 Thousand CAD | 55.9% |
| 2013 | 219.47 Thousand CAD | 119.88% |
| 2012 | 99.81 Thousand CAD | 833.02% |
| 2011 | 10.69 Thousand CAD | 113.96% |
| 2010 | 5000.00 CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 630.39 Thousand CAD | -46.23% |
| 2024 FY | 245.23 Thousand CAD | -79.34% |
| 2024 Q4 | 245.23 Thousand CAD | -61.1% |
| 2024 Q1 | 1.09 Million CAD | -7.86% |
| 2024 Q2 | 1.17 Million CAD | 7.18% |
| 2023 Q1 | 1.43 Million CAD | 2.98% |
| 2023 FY | 1.18 Million CAD | -14.94% |
| 2023 Q4 | 1.18 Million USD | -6.8% |
| 2023 Q3 | 1.27 Million CAD | -21.65% |
| 2023 Q2 | 1.62 Million CAD | 13.12% |
| 2022 Q3 | 380.16 Thousand CAD | -27.57% |
| 2022 FY | 1.39 Million CAD | 179.15% |
| 2022 Q4 | 1.39 Million CAD | 267.14% |
| 2022 Q2 | 524.83 Thousand CAD | -30.26% |
| 2022 Q1 | 752.54 Thousand CAD | 50.51% |
| 2021 Q4 | 500 Thousand CAD | -87.73% |
| 2021 Q2 | 3.28 Million CAD | -0.02% |
| 2021 FY | 500 Thousand CAD | -89.37% |
| 2021 Q1 | 3.28 Million CAD | -30.22% |
| 2021 Q3 | 4.07 Million CAD | 24.19% |
| 2020 Q3 | 905.89 Thousand CAD | -9.64% |
| 2020 FY | 4.7 Million CAD | 34.44% |
| 2020 Q1 | 4.04 Million CAD | 15.59% |
| 2020 Q2 | 1 Million CAD | -75.2% |
| 2020 Q4 | 4.7 Million CAD | 419.07% |
| 2019 Q4 | 3.49 Million CAD | -2.07% |
| 2019 Q3 | 3.57 Million CAD | -34.38% |
| 2019 Q2 | 5.44 Million CAD | 2.56% |
| 2019 FY | 3.49 Million CAD | 1309.23% |
| 2019 Q1 | 5.3 Million CAD | 2038.23% |
| 2018 Q4 | 248.19 Thousand CAD | -4.32% |
| 2018 Q3 | 259.4 Thousand CAD | -47.18% |
| 2018 Q2 | 491.11 Thousand CAD | -1.66% |
| 2018 Q1 | 499.4 Thousand CAD | 38.57% |
| 2018 FY | 248.19 Thousand CAD | -31.13% |
| 2017 Q4 | 360.38 Thousand CAD | 88.4% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 FY | 360.38 Thousand CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q3 | 191.29 Thousand CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2015 Q4 | - CAD | -100.0% |
| 2015 FY | - CAD | -100.0% |
| 2015 Q3 | 392.93 Thousand CAD | 8.01% |
| 2015 Q2 | 363.8 Thousand CAD | 2.38% |
| 2015 Q1 | 355.32 Thousand CAD | 3.85% |
| 2014 Q3 | 242.13 Thousand CAD | 6.81% |
| 2014 Q2 | 226.7 Thousand CAD | 2.35% |
| 2014 Q1 | 221.5 Thousand CAD | 0.92% |
| 2014 FY | 342.15 Thousand CAD | 55.9% |
| 2014 Q4 | 342.15 Thousand CAD | 41.31% |
| 2013 Q4 | 219.47 Thousand CAD | 631.58% |
| 2013 Q1 | 139.5 Thousand CAD | 39.76% |
| 2013 Q2 | 162.35 Thousand CAD | 16.38% |
| 2013 FY | 219.47 Thousand CAD | 119.88% |
| 2013 Q3 | 30 Thousand CAD | -81.52% |
| 2012 Q1 | 192.87 Thousand CAD | 1702.91% |
| 2012 Q2 | 132.13 Thousand CAD | -31.49% |
| 2012 Q3 | 91.6 Thousand CAD | -30.67% |
| 2012 Q4 | 99.81 Thousand CAD | 8.96% |
| 2012 FY | 99.81 Thousand CAD | 833.02% |
| 2011 FY | 10.69 Thousand CAD | 113.96% |
| 2011 Q1 | 5000.00 CAD | 0.0% |
| 2011 Q2 | - CAD | -100.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | 10.69 Thousand CAD | 0.0% |
| 2010 FY | 5000.00 CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.405% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 94.051% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.107% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.435% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.176% |
| Mesoblast Limited | 118.7 Million USD | 99.793% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 74.139% |
| Genus plc | 233.1 Million USD | 99.895% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 91.631% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 81.748% |
| Marizyme, Inc. | 18.71 Million USD | 98.69% |
| ContraFect Corporation | 2.88 Million USD | 91.488% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 67.302% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -81.002% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 83.044% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 89.457% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 95.666% |
| MultiCell Technologies, Inc. | 202.58 USD | -120955.386% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.573% |
| EV Biologics, Inc. | 1.49 Million USD | 83.594% |
| Q BioMed Inc. | 4.1 Million USD | 94.033% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.259% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 61.079% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 80.036% |
| Biomind Labs Inc. | 735.54 Thousand USD | 66.659% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.857% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.113% |
| Skye Bioscience, Inc. | 4.61 Million USD | 94.686% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 72.386% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -73.288% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 95.823% |
| IMV Inc. | 28.88 Million USD | 99.151% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -853.513% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 89.141% |
| GB Sciences, Inc. | 1.75 Million USD | 86.061% |
| Alpha Cognition Inc. | 1.22 Million USD | 79.905% |
| HST Global, Inc. | 98.31 Thousand USD | -149.427% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Halberd Corporation | 150 Thousand USD | -63.489% |
| Enzolytics Inc. | 996.33 Thousand USD | 75.386% |
| Resverlogix Corp. | 6.49 Million USD | 96.222% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 48.642% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 4.053% |
| argenx SE | 20 Million USD | 98.774% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.462% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 90.946% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2298.377% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.941% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -22.24% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 89.772% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -6.953% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.637% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 91.896% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 31.825% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.794% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -64.97% |
| BioStem Technologies, Inc. | 4.71 Million USD | 94.795% |
| ONE Bio Corp. | 19.71 Million USD | 98.756% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 1.978% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 1.402% |
| Agentix Corp. | 50 Thousand USD | -390.468% |
| LadRx Corporation | 33.6 Thousand USD | -629.733% |
| Cell Source, Inc. | 9.25 Million USD | 97.35% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 67.57% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 67.57% |
| NovAccess Global Inc. | 2.19 Million USD | 88.852% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 96.533% |
| Itoco Inc. | 228.37 Thousand USD | -7.381% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -16.238% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 95.079% |
| Kadimastem Ltd | 891.22 Thousand USD | 72.484% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 38.974% |
| CytoDyn Inc. | 30.07 Million USD | 99.185% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 49.362% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 30.301% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 96.864% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -100.191% |
| Rebus Holdings, Inc. | 310 Thousand USD | 20.892% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 94.821% |
| International Stem Cell Corporation | 4.17 Million USD | 94.13% |
| Bioxytran, Inc. | 1.92 Million USD | 87.261% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -292.921% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 88.755% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 97.051% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.143% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 84.234% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 8.495% |
| Neutra Corp. | 54.15 Thousand USD | -352.829% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 86.599% |
| PureTech Health plc | 25.51 Million USD | 99.039% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 79.968% |
| IXICO plc | 472.02 Thousand USD | 48.046% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.418% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.606% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.736% |